In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Controversies in heart failure
Session

Event : ESC Congress 2016

Topic : Chronic Heart Failure – Pathophysiology and Mechanisms

  • Session type : Debate Session
  • Date : 27 August 2016
  • Time : 11:00 - 12:30

6 presentations in this session

Controversies in heart failure - Introduction to the session

Event : ESC Congress 2016

  • Session : Controversies in heart failure
  • Speaker : C Yancy (Chicago,US)

ACE - inhibitors should be replaced by LCZ696 as first line therapy for heart failure - PRO

Event : ESC Congress 2016

  • Session : Controversies in heart failure
  • Speaker : JJV McMurray (Glasgow,GB)

ACE - inhibitors should be replaced by LCZ696 as first line therapy for heart failure - CON

Event : ESC Congress 2016

  • Session : Controversies in heart failure
  • Speaker : GMC Rosano (London,GB)

B-Blockers and digoxin should be forgotten in atrial fibrillation heart failure - PRO

Event : ESC Congress 2016

  • Session : Controversies in heart failure
  • Speaker : S Hohnloser (Koenigstein,DE)

B-Blockers and digoxin should be forgotten in atrial fibrillation heart failure - CON

Event : ESC Congress 2016

  • Session : Controversies in heart failure
  • Speaker : J Bauersachs (Hannover,DE)

Controversies in heart failure - Conclusion

Event : ESC Congress 2016

  • Session : Controversies in heart failure
  • Speaker : S Anker (Berlin,DE)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are